Grants
2021
Joint funding from the Chief Scientist Office (CSO) and independent medical charity LifeArc to support rare disease translational research to accelerate scientific discoveries to deliver new clinical interventions for patients living with a rare condition has been awarded in 2021 to conduct a pre-clinical study titled “Does antiRANKL therapy prevent glucocorticoid related bone loss in mice model of DMD?”
2020
Glasgow's neuromuscular team became a UK DMD Hub in 2020, with funding received for three posts; Consultant Paediatric Neurologist, Trial Coordinator, and Research Physiotherapist, increasing research capacity and improved patient access to clinical trials in DMD.
2015
The Chief Scientist Office, Muscular Dystrophy UK and Action Duchenne awarded funds for a clinical academic fellowship to conduct a study entitled "Secondary osteoporosis & its therapy in Duchenne Muscular Dystrophy” in 2015.